Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYRA Stock Price Chart Interactive Chart >
TYRA Price/Volume Stats
| Current price | $7.92 | 52-week high | $31.36 |
| Prev. close | $7.67 | 52-week low | $6.25 |
| Day low | $7.45 | Volume | 48,700 |
| Day high | $8.15 | Avg. volume | 100,335 |
| 50-day MA | $9.30 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 330.75M |
Tyra Biosciences, Inc. (TYRA) Company Bio
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest TYRA News From Around the Web
Below are the latest news stories about Tyra Biosciences Inc that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences surges 14% as owner Boxer Capital buys 125,000 sharesNo summary available. |
Tyra Biosciences Inc (NASDAQ:TYRA) Major Shareholder Boxer Capital, Llc Acquires 125,000 SharesTyra Biosciences Inc (NASDAQ:TYRA) major shareholder Boxer Capital, Llc acquired 125,000 shares of the businesss stock in a transaction that occurred on Friday, December 17th. The stock was bought at an average cost of $13.12 per share, for a total transaction of $1,640,000.00. The purchase was disclosed in a filing with the Securities & Exchange [] |
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc. |
Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX)Tyra Biosciences (NASDAQ:TYRA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Insider and Institutional Ownership 51.6% of Tyra Biosciences shares are held by institutional investors. Comparatively, [] The post Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX) appeared first on ETF Daily News . |
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
TYRA Price Returns
| 1-mo | 11.55% |
| 3-mo | -33.94% |
| 6-mo | -68.29% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -43.71% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...